136 related articles for article (PubMed ID: 28662141)
21. Gene expression profiling of primary cutaneous melanoma and clinical outcome.
Winnepenninckx V; Lazar V; Michiels S; Dessen P; Stas M; Alonso SR; Avril MF; Ortiz Romero PL; Robert T; Balacescu O; Eggermont AM; Lenoir G; Sarasin A; Tursz T; van den Oord JJ; Spatz A;
J Natl Cancer Inst; 2006 Apr; 98(7):472-82. PubMed ID: 16595783
[TBL] [Abstract][Full Text] [Related]
22. Uveal and cutaneous melanoma: shared expression characteristics of melanoma-associated antigens.
van Dinten LC; Pul N; van Nieuwpoort AF; Out CJ; Jager MJ; van den Elsen PJ
Invest Ophthalmol Vis Sci; 2005 Jan; 46(1):24-30. PubMed ID: 15623750
[TBL] [Abstract][Full Text] [Related]
23. RASSF8 regulates progression of cutaneous melanoma through nuclear factor-κb.
Wang J; Hua W; Huang SK; Fan K; Takeshima L; Mao Y; Hoon DS
Oncotarget; 2015 Oct; 6(30):30165-77. PubMed ID: 26334503
[TBL] [Abstract][Full Text] [Related]
24. Prognostic value of BRAF mutations in localized cutaneous melanoma.
Nagore E; Requena C; Traves V; Guillen C; Hayward NK; Whiteman DC; Hacker E
J Am Acad Dermatol; 2014 May; 70(5):858-62.e1-2. PubMed ID: 24388723
[TBL] [Abstract][Full Text] [Related]
25. Lack of BRAF mutations in uveal melanoma.
Rimoldi D; Salvi S; Liénard D; Lejeune FJ; Speiser D; Zografos L; Cerottini JC
Cancer Res; 2003 Sep; 63(18):5712-5. PubMed ID: 14522889
[TBL] [Abstract][Full Text] [Related]
26. Epidemiology and survival outcomes of ocular and mucosal melanomas: a population-based analysis.
Bishop KD; Olszewski AJ
Int J Cancer; 2014 Jun; 134(12):2961-71. PubMed ID: 24272143
[TBL] [Abstract][Full Text] [Related]
27. Melanomas of unknown primary frequently harbor TERT-promoter mutations.
Egberts F; Krüger S; Behrens HM; Bergner I; Papaspyrou G; Werner JA; Alkatout I; Haag J; Hauschild A; Röcken C
Melanoma Res; 2014 Apr; 24(2):131-6. PubMed ID: 24463461
[TBL] [Abstract][Full Text] [Related]
28. Distinct clinical features of paraganglioma syndromes associated with SDHB and SDHD gene mutations.
Neumann HP; Pawlu C; Peczkowska M; Bausch B; McWhinney SR; Muresan M; Buchta M; Franke G; Klisch J; Bley TA; Hoegerle S; Boedeker CC; Opocher G; Schipper J; Januszewicz A; Eng C;
JAMA; 2004 Aug; 292(8):943-51. PubMed ID: 15328326
[TBL] [Abstract][Full Text] [Related]
29. Loss of membranous expression of beta-catenin is associated with tumor progression in cutaneous melanoma and rarely caused by exon 3 mutations.
Demunter A; Libbrecht L; Degreef H; De Wolf-Peeters C; van den Oord JJ
Mod Pathol; 2002 Apr; 15(4):454-61. PubMed ID: 11950921
[TBL] [Abstract][Full Text] [Related]
30. MicroRNA expression profiles associated with mutational status and survival in malignant melanoma.
Caramuta S; Egyházi S; Rodolfo M; Witten D; Hansson J; Larsson C; Lui WO
J Invest Dermatol; 2010 Aug; 130(8):2062-70. PubMed ID: 20357817
[TBL] [Abstract][Full Text] [Related]
31. Frequent germ-line succinate dehydrogenase subunit D gene mutations in patients with apparently sporadic parasympathetic paraganglioma.
Dannenberg H; Dinjens WN; Abbou M; Van Urk H; Pauw BK; Mouwen D; Mooi WJ; de Krijger RR
Clin Cancer Res; 2002 Jul; 8(7):2061-6. PubMed ID: 12114404
[TBL] [Abstract][Full Text] [Related]
32. Distribution of TERT promoter mutations in primary and metastatic melanomas in Austrian patients.
Ofner R; Ritter C; Heidenreich B; Kumar R; Ugurel S; Schrama D; Becker JC
J Cancer Res Clin Oncol; 2017 Apr; 143(4):613-617. PubMed ID: 27990595
[TBL] [Abstract][Full Text] [Related]
33. Significant impact of promoter hypermethylation and the 540 C>T polymorphism of CDKN2A in cutaneous melanoma of the vertical growth phase.
Straume O; Smeds J; Kumar R; Hemminki K; Akslen LA
Am J Pathol; 2002 Jul; 161(1):229-37. PubMed ID: 12107107
[TBL] [Abstract][Full Text] [Related]
34. Prognostic relevance of lactate dehydrogenase and serum S100 levels in stage IV melanoma with known BRAF mutation status.
Frauchiger AL; Mangana J; Rechsteiner M; Moch H; Seifert B; Braun RP; Dummer R; Goldinger SM
Br J Dermatol; 2016 Apr; 174(4):823-30. PubMed ID: 26659191
[TBL] [Abstract][Full Text] [Related]
35. BH3-only protein Bim predicts advanced stage of cutaneous melanoma.
Gambichler T; Rooms I; Scholl L; Stockfleth E; Stücker M; Sand M
J Eur Acad Dermatol Venereol; 2016 Nov; 30(11):1926-1929. PubMed ID: 27356803
[TBL] [Abstract][Full Text] [Related]
36. Clinicopathological characteristics and mutation profiling in primary cutaneous melanoma.
Yaman B; Akalin T; Kandiloğlu G
Am J Dermatopathol; 2015 May; 37(5):389-97. PubMed ID: 25357015
[TBL] [Abstract][Full Text] [Related]
37. Prognostic significance of MGMT gene promoter methylation in differently treated metastatic melanomas.
Cesinaro AM; Sartori G; Migaldi M; Schirosi L; Pellacani G; Collina G; Maiorana A
Pathology; 2012 Jun; 44(4):313-7. PubMed ID: 22544212
[TBL] [Abstract][Full Text] [Related]
38. BRAF-V600E expression in primary nodular melanoma is associated with aggressive tumour features and reduced survival.
Hugdahl E; Kalvenes MB; Puntervoll HE; Ladstein RG; Akslen LA
Br J Cancer; 2016 Mar; 114(7):801-8. PubMed ID: 26924424
[TBL] [Abstract][Full Text] [Related]
39. No difference in phenotype of the main Dutch SDHD founder mutations.
van Hulsteijn LT; den Dulk AC; Hes FJ; Bayley JP; Jansen JC; Corssmit EP
Clin Endocrinol (Oxf); 2013 Dec; 79(6):824-31. PubMed ID: 23586964
[TBL] [Abstract][Full Text] [Related]
40. PUMA expression is significantly reduced in human cutaneous melanomas.
Karst AM; Dai DL; Martinka M; Li G
Oncogene; 2005 Feb; 24(6):1111-6. PubMed ID: 15690057
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
